LL-37

Overview

LL-37 is the only member of the cathelicidin family of antimicrobial peptides found in humans. It is released from a precursor protein called hCAP18 and is produced by immune cells and epithelial surfaces such as the skin, gut, and airways, where it forms part of the body’s first line of innate immune defense.

Interest in LL-37 centers on its unusually broad functional range. It is studied for direct activity against bacteria, fungi, and viruses, for its ability to interfere with bacterial biofilms, and for its role as a signaling molecule that helps coordinate the immune response to infection.

Most of the available evidence comes from laboratory and animal studies. Human clinical data is limited, and LL-37 is not approved by any major regulator as a therapeutic drug.

How it works

LL-37 carries a net positive charge and is amphipathic, which lets it target the negatively charged membranes of many microbes. In preclinical work it is described as disrupting bacterial membranes directly, while also reducing bacterial attachment to surfaces and interfering with the structure of established biofilms.

Beyond its antimicrobial action, researchers have reported that LL-37 acts as an immune modulator, or “alarmin” — influencing how neutrophils and macrophages respond to infection, shaping inflammation, and contributing to wound healing and angiogenesis. The precise mechanisms and relevance of these effects in humans are still being characterized.

Reported benefits

• Broad-spectrum activity studied against bacteria, fungi, and viruses (largely preclinical)
• Disruption of bacterial biofilms, including some drug-resistant strains (laboratory data)
• Modulation of the immune and inflammatory response
• Studied roles in wound healing and tissue defense

These are reported and studied effects, not guaranteed outcomes.

Considerations & side effects

Because well-controlled human trials are lacking, the safety profile of supplemental LL-37 is not well established. Laboratory research has noted that LL-37 can be cytotoxic to human cells at higher concentrations, and that it has limited stability, which are among the reasons its clinical use remains investigational.

LL-37 has also been linked to inflammatory processes in conditions such as rosacea and psoriasis, so its biology is not uniformly beneficial. Product purity varies in the research-chemical market, and LL-37 is not a substitute for evaluation and treatment by a qualified clinician.